Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Eliot N. Mostow MD, MPH Associate Editor

Robert T. Brodell MD, FAAD Editor-in-Chief

Ashish C. Bhatia MD, FAAD Associate Editor

See All Experts

featured

Published in Dermatology

Journal Scan / Research · August 27, 2018

Dupilumab Does Not Affect Correlates of Vaccine-Induced Immunity

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Andrew Blauvelt MD, MBA

Journal of the American Academy of Dermatology

Dupilumab Does Not Affect Correlates of Vaccine-Induced Immunity: A Randomized, Placebo-Controlled Trial in Adults With Moderate-to-Severe Atopic Dermatitis

J Am Acad Dermatol 2018 Aug 06;[EPub Ahead of Print], A Blauvelt, EL Simpson, SK Tyring, LA Purcell, B Shumel, CD Petro, B Akinlade, A Gadkari, L Eckert, NMH Graham, G Pirozzi, R Evans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Dupilumab Does Not Affect Correlates of Vaccine-Induced Immunity

Additional Info

Dupilumab Does Not Affect Correlates of Vaccine-Induced Immunity: A Randomized, Placebo-Controlled Trial in Adults With Moderate-to-Severe Atopic Dermatitis

Further Reading

Evaluation and Surgical Management of Pediatric Cutaneous Melanoma, Atypical Spitz Tumors, and Non-Spitz Melanocytic Tumors

Safety of Biologic Use During Pregnancy and Breastfeeding in Dermatology

Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Efficacy of Treatment With Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis Through 76 Weeks

Non-SCORTEN Predictors of Mortality Among Patients With SJS/TEN

Risk Factors for Subclinical Spread in Patients With Melanoma In Situ and Invasive Melanoma

Outcomes of Dermoscopic vs Naked-Eye Evaluation of Surgical Margins in Patients With Nonmelanoma Skin Cancer Undergoing Mohs Micrographic Surgery

Recently Updated